跳至主要内容
临床试验/NCT00107926
NCT00107926已完成3 期

Study of Licarbazepine in the Treatment of Manic Episodes of Bipolar Disorder

Novartis Pharmaceuticals4 个研究点 分布在 4 个国家目标入组 343 人开始时间: 2004年10月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
已完成
入组人数
343
试验地点
4
主要终点
Mean reduction in manic episodes and major depressive episodes from baseline to endpoint (week 6).

研究概览

简要总结

The purpose of this study is to evaluate the effectiveness and tolerability of an investigational drug for the treatment of manic episodes of bipolar disorder. The investigational drug will be given as additional treatment with either lithium or valproate, which are already FDA (Food and Drug Administration)-approved treatments for mania.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Diagnosis of bipolar disorder (type I) with manic or mixed episodes (including patients with/without psychotic features or with/without a history of rapid cycling)
  • In need of psychiatric treatment
  • Cooperation and willingness to complete all aspects of the study

排除标准

  • Current diagnosis other than bipolar I disorder
  • History of schizophrenia or schizoaffective disorder
  • Drug dependence within 1 month prior to study start or testing positive in a urine drug test
  • Suicide attempt within 1 month prior to study start or at immediate risk of harm to self or others
  • Any form of psychotherapy within 1 month prior to study start

研究组 & 干预措施

licarbazepine

Experimental

干预措施: Licarbazepine (Drug)

Placebo

Placebo Comparator

干预措施: Placebo (Drug)

结局指标

主要结局

Mean reduction in manic episodes and major depressive episodes from baseline to endpoint (week 6).

次要结局

  • Major improvement in anxiety and depression from baseline to endpoint (week 6)

研究者

申办方类型
Industry

研究点 (4)

Loading locations...

相似试验

Study of Licarbazepine in the Treatment of Manic... | 临床试验